Patent SG-11201803732P-A (SG)
Title: Novel anti-angiogenic fusion polypeptides
Inventor: OLWILL SHANE
IPC: C07K19/00
Filed: 2016-11-30
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau res.. 00) (43) International Publication Date .... .....r el 8 June 2017 (08.06.2017) W I P0 1 PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/091850 Publication Number Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 19/00 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/22 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/AU2016/051168 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 30 November 2016 (30.11.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 15197019.1 30 November 2015 (30.11.2015) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PIERIS AUSTRALIA PTY LTD. [AU/AU]; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Level 8 Angel Place, 123 Pitt Street, Sydney, New South TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Wales 2000 (AU). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: OLWILL, Shane; Am Waldrand 23a, 85354 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Freising (DE). BEL MBA, Rachida Siham; Er- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, hardtstrasse 15, 80469 Munich (DE). WIEDENMANN, Alexander; Fuersteneckerstrasse 5, D-89077 Ulm (DE). GW, KM, ML, MR, NE, SN, TD, TG). Published: (74) Agent: FISHER ADAMS KELLY CALLINANS; Level 6, 175 Eagle Street, Brisbane, Queensland 4000 (AU). — with international search report (Art 21(3)) [Continued on next page] (54) Title: NOVEL ANTI-ANGIOGENIC FUSION POLYPEPTIDES (57) : The disclosure provides fusion polypeptides comprising a Figure 1 for Ang-2 for fusion moiety specific and another VEGF-A, which poly- be for antagonizing Ang-2 and VEGF-A. In a peptide can useful pre- ferred embodiment, the Ang-2-specific moiety is comprised of a human lipocalin Such fusion =\ (hNGAL) mutein. \ , % 'c neutrophil gelatinase associated , ,,, % polypeptide can be used in many phannaceutical applications, for ex- b\ ' ample, as an agent useful to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making the fusion polypeptides de- • ; 3 1 scribed herein as well as compositions comprising such fusion - poly V \" peptides. The present disclosure further relates to nucleic acid molecules encoding such fusion their amino acid sequences and to polypeptides, for fusion methods the generation of such polypeptides and nucleic acid molecules. In addition, the application discloses therapeutic and/or dia - SW O's: hand 11 SEQ ID ND's: 9 and 10 gnostic uses of such fusion polypeptide as well as compositions compris- ing one or more of such fusion polypeptides. \ • t ., \• kk4k kV Il ki . 4t in Ot C:: , Il Cr1 SEQ ID ND's: S 0 ---.... IN 11 0 ei $ and 15 SEQ ID NO's: 9 and 14 O WO 2017/091850 Al IMEDIMOMOI VIII IIIII VIII F 0 10 IIMMOEIMI00110MOVOIMIE — before the expiration of the time limit for amending the — with sequence listing part of description (Rule 5.2(a)) claims and amendments to be (Rule republished 48.2(h)) in the event of receipt of